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The four isomers of 9-butylphosphabicyclo[3.3.1]nonane (s-PhobPBu, where Bu = n-, sec-, iso-
and tert-butyl)) have been prepared. Seven isomers of 9-butylphosphabicyclo[4.2.1]nonane (a5-
PhobPBu, where Bu = n-, iso-, sec- and tert-butyl; a7-PhobPBu, where Bu = n-, iso-, sec- and 
tert-butyl) have been identified in solution and some of the a5 isomers have been isolated. The 
donor properties of the PhobPBu ligands have been compared in the light of the JPSe values for 
PhobP(=Se)Bu isomers and νCO for the trans-[RhCl(CO)(PhobPBu)2] complexes. The following 
complexes have been prepared: trans-[MCl2(s-PhobPR)2] M = Pt, R = nBu (1a), iBu (1b), sBu 
(1c), tBu (1d); trans-[MCl2(a5-PhobPR)2] M = Pt, R = nBu (2a), iBu (2b); trans-[MCl2(a7-
PhobPR)2] M = Pt, R = nBu (3a), iBu (3b); trans-[MCl2(s-PhobPR)2] M = Pd, R = nBu (4a), iBu 
(4b); trans-[MCl2(a5-PhobPR)2] M = Pd, R = nBu (5a), iBu (5b); trans-[MCl2(a7-PhobPR)2] M = 
Pd, R = nBu (6a), iBu (6b). The crystal structures of 1-4a and 1-6b have been determined and of 
the 10 structures, 8 show an anti conformation with respect to the position of the ligand R groups 
and 2 show a syn conformation. Solution variable-temperature 31P NMR studies reveal that all of 
the Pt and Pd complexes are fluxional on the NMR timescale. In each case, two species are 
present (assigned to be the syn and anti conformers) which interconvert with kinetic barriers in 
the range 9 to >19 kcal mol-1. The greater the bulk of the R group of the PhobPR ligand, the 
higher the barrier. The magnitude of the rotation barriers for the PhobPR complexes are of the 
same order as those previously reported for tBu2PR complexes. Rotational profiles have been 
calculated for the model anionic complexes [PhobPR–PdCl3]– using DFT and these faithfully 
reproduce the trends seen in the NMR studies of trans-[MCl2(PhobPR)2]. Rotational profiles have 
also been calculated for [tBu2PR–PdCl3]– and these show that the greater the bulk of the R group, 
the lower the rotational barrier, i.e. the opposite trend to [PhobPR–PdCl3]–. Calculated structures 
for the species at the maxima and minima in the curves indicate the origin of the restricted 
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rotation. In the case of the PhobPR complexes, it is the rigidity of the bicycle that enforces 
unfavorable H....Cl clashes involving the Pd–Cl groups with H atoms on the α- or β-carbon in the 
R substituent and H atoms in 1,3-axial sites within the phosphabicycle. 
KEYWORDS. bicyclic phosphines, stereoelectronic effects, rotamers, fluxionality, platinum 





The bicyclic tertiary phosphines known as phobanes (Chart 1)1 were amongst the first tertiary 
phosphines to find application in industrial homogeneous catalysis: Shell’s cobalt-catalysed 
reductive hydroformylation of long-chain alkenes is based on tertiary phobanes and has operated 
for over 40 years.2 Subsequently, tertiary phobanes have found many other applications in 
homogeneous catalysis,3 and it is therefore of interest to explore the properties of their 
complexes4 in the hope of providing insight into why phobanes are privileged ligands for certain 










Here we report s-, a5- and a7-PhobPBu (Bu = n-, iso-, sec- and tert-butyl) and show that the 
complexes trans-[MCl2(PhobPBu)2] (M = Pt or Pd) are fluxional as a result of restricted M–P 
rotation. This observation runs counter to the prevailing maxim that there is essentially free 
rotation about M–P bonds unless the P-ligand contains very bulky substituents (e.g. tBu2PR) or 
the adjacent ligands are very bulky,5,6,7 We report computational studies which suggest that it is 
the rigidity of the bicycle that is the source of the high barriers to M–P rotation in PhobPR 
complexes. The discovered high rigidity of PhobPR complexes may be significant in 
understanding the differences between the properties of complexes of phobanes and their acyclic 
analogues. It also shows that in one important respect, the coordination chemistry of the non-
bulky PhobPR ligands resembles that of the omnipresent and very bulky tBu2PR ligands.  
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Results and Discussion 
Phobanes exist in the three diastereoisomeric forms shown in Chart 1 and we have previously 
reported1 the diastereospecific synthesis of s-, a5- and a7-PhobPnBu. The isomeric butylphobanes 
in Chart 2 have now all been prepared, mostly as single diastereoisomers, by one of the routes 
shown in Scheme 1 (see Experimental for details). Others8 have shown that s-PhobPiBu (as a 
mixture of diastereoisomers) can be prepared by hydrophosphination of 1,5-cyclooctadiene with 
iBuPH2. All of the new phosphines were purified by distillation and characterized by a 

































R = iBu,  sBu
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Samples of the butylphobanes shown in Chart 2 were converted to the corresponding selenides 
by treatment with KSeCN in MeOH and the PhobP(Se)R species were characterized by 31P NMR 
spectroscopy and mass spectrometry. The values for JPSe are collected in Table 1 and these can be 
used to evaluate the σ−donor properties of the ligands. Roodt et al.9 have shown that the smaller 
the value of JPSe, the greater the σ-donation capacity of the ligand; to calibrate the values given in 
Table 1, JPSe values for CynPh3-nP=Se are 673 Hz (n = 3), 701 Hz (n = 2) and 725 Hz (n = 1).9 The 
data in Table 1 clearly show that the order of strength of σ-donation is consistently in the order a7 
> s > a5. The effect of the R groups can be gauged from the JPSe values for s- and a5-PhobP(Se)R 
which are in the order tBu > iBu > nBu > sBu; the anomalous position of sBu in this series shows 
that the order is not simply the product of inductive effects of the R groups. 
The crystal structures of the three diastereoisomers of PhobP(Se)nBu have been determined 
(Figure 1). The deviation from tetrahedral geometry at the phosphorus atom (C-P-C angle) is 
significant and most pronounced in the asym isomers. The conformations of the n-butyl 
substituents are quite different in the crystal structures of the three PhobP(Se)nBu isomers; the 
Se1-P1-C9-C10 torsion angles are 61˚ for the s, 49˚ for the a5 and 45˚ for the a7 isomers. This 
unduly influences the crystallographically determined cone angles for the three ligands but if the 
cone angles are determined by encompassing only the C9 atoms of the n-butyl groups, the values 




 (a) (b) (c) 
Figure 1. Crystal structures of the isomers of PhobP(Se)nBu (hydrogen atoms omitted for 
clarity). Selected bond lengths (Å) and angles (°): (a) s-PhobP(Se)nBu: Se(1)-P(1), 2.1313(4); 
C(1)-P(1)-C(5), 97.22(4); (b) a5-PhobP(Se)nBu: Se(1)-P(1), 2.1196(4); C(1)-P(1)-C(4), 94.04(6); 
(c) a7-PhobP(Se)nBu: Se(1)-P(1), 2.1259(5); C(1)-P(1)-C(4), 93.63(9). 
Table 1. Values of JPSe for PhobP(Se)Ra  
R JPSe / Hz 
 s-PhobP(Se)R a5-PhobP(Se)R a7-PhobP(Se)R 
nBu 684 707 662 
iBu 679 703 b 
sBu 688 712 b 
tBu 678 705 648 
a Spectra measured in CDCl3 
b Compound not observed. 
Platinum(II) and palladium(II) complexes. The complexes trans-[PtCl2(PhobPBu)2] where 
M = Pt or Pd (Chart 3) were prepared by the addition of single diastereoisomers of PhobPBu to 
[PtCl2(NCtBu)2] or [PdCl2(NCPh)2]. The trans geometry of the platinum complexes in solution 
was assigned on the basis of the values of JPtP which lie in the range 2200-2600 Hz (Table 2), 
typical of trans-[PtCl2(PR3)2].10 The trans geometry of the palladium complexes was assigned on 
 
8 


















R =  nBu
4
R =  sBu R =  tBu
5 6





















R =  iBu  
Table 2. 31P NMR data for complexes trans-[MCl2(PhobPBu)2] where M = Pt or Pd.a 
Complex R δP / ppm JPPt / Hz Tc / ˚C ΔG‡ / kcal mol-1 
1a nBu 4.1 2437  –30 12 
1b iBu 4.2, 3.2 2502, 2502  +50 15 
1c (R)-sBu 9.3, 7.8 2493, 2614  +20 14 
1d tBu 19.8, 19.6 2231, 2231  >100 >19 
2a nBu 40.7 2411 -10  
2b iBu 38.4, 37.8 2404, 2407  +70 17 
3a nBu 34.5 2311  –80 9 
3b iBu 31.6 2305  –30 12 
4a nBu 9.5   –30 11 
4b iBu 8.6, 7.2   +50 15 
5a nBu 48.1   –30 12 
5b iBu 46.2, 45.4   +60 16 
6a nBu 39.5   –100 8 
6b iBu 37.8   –50 11 
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a Spectra at low temperatures were measured in CD2Cl2 and at high temperatures were 
measured in C2D2Cl4. 
The crystal structures of the n-butylphobane complexes 1-4a are shown in Figure 2; the structures 
of 1a and 3a were previously reported.1 The crystal structures of the i-butylphobane complexes 1-
6b are shown in Figure 3. In all but two of these ten crystal structures, the R substituents are on 
opposite sides of the square plane (anti); the exceptions are 3b and 6b where the substituents are 
on the same side of the square plane (syn). In fact, in all but 3b and 6b, the metal atom sits on an 
inversion centre, such that the trans phosphines are related by crystallographic inversion 
symmetry (i.e. torsion angle C(9)-P(1)…P(1A)-C(9A) = 180°). 
 
Figure 2. Crystal structures of trans-[MCl2(PhobPnBu)2]. All hydrogen atoms omitted for clarity. 
Ellipsoids drawn at 50% probability. Selected bond lengths and angles: 1a1: Pt(1)-Cl(1), 
2.3060(10); Pt(1)-P(1), 2.3121(10); C(1)-P(1)-C(5), 95.87(15); Cl(1)-Pt(1)-P(1)-C(9), 89.92(12); 
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C(9)-P(1)-P(1A)-C(9A), 180.0. 2a: Pt(1)-Cl(1), 2.3155(16); Pt(1)-P(1), 2.3079(16); C(1)-P(1)-
C(4), 93.1(3); Cl(1)-Pt(1)-P(1)-C(9), 88.8(3); C(9)-P(1)-P(1A)-C(9A), 180.0. 3a1: Pt(1)-Cl(1), 
2.319(4); Pt(1)-P(1), 2.321(4); C(1)-P(1)-C(6), 97.2(8); Cl(1)-Pt(1)-P(1)-C(9), 71.1(7); C(9)-
P(1)-P(1A)-C(9A), 180.0; Pt(1)-P(1)-C(9)-C(10), 32(2). 4a: Pd(1)-Cl(1), 2.3082(12); Pd(1)-P(1), 
2.3221(13); C(1)-P(1)-C(5), 96.5(3); Cl(1)-Pd(1)-P(1)-C(9), -89.9(2); C(9)-P(1)-P(1A)-C(9A), 
180.0. 
 
Figure 3. Crystal structures of trans-[MCl2(PhobPiBu)2]. All hydrogen atoms omitted for clarity. 
Ellipsoids drawn at 50% probability. Selected bond lengths and angles: 1b: Pt(1)-Cl(1), 
2.3156(6); Pt(1)-P(1), 2.3133(6); C(1)-P(1)-C(5), 96.18(12); Cl(1)-Pt(1)-P(1)-C(9), 72.32(9); 
C(9)-P(1)-P(1A)-C(9A), 180.0. 2b: Pt(1)-Cl(1), 2.315(2); Pt(1)-Cl(2), 2.315(2); Pt(1)-P(1), 
2.311(2); Pt(1)-P(2), 2.321(2); C(1)-P(1)-C(6), 93.7(5); C(13)-P(1)-C(18), 93.4(4); Cl(1)-Pt(1)-
P(1)-C(9), -71.1(4); Cl(2)-Pt(1)-P(2)-C(21A), 68.3(4); C(9)-P(1)-P(2)-C(21A), 177.3 (5). 3b: 
Pt(1)-Cl(1), 2.3111(6); Pt(1)-Cl(2), 2.3208(6); Pt(1)-P(1), 2.3161(7); Pt(1)-P(2), 2.3150(7); C(1)-
P(1)-C(4), 93.04(12); C(13)-P(1)-C(16), 93.33(11); Cl(1)-Pt(1)-P(1)-C(9), -121.53(10); Cl(2)-
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Pt(1)-P(2)-C(21), -68.69(9); C(9)-P(1)-P(2)-C(21), -10.2(1). 4b: Pd(1)-Cl(1), 2.3096(18); Pd(1)-
P(1), 2.3232(19); C(1)-P(1)-C(5), 96.3(4); Cl(1)-Pd(1)-P(1)-C(9), -108.3(3); C(9)-P(1)-P(1A)-
C(9A), 180.0. 5b: Pd(1)-Cl(1), 2.3178(6); Pd(1)-P(1), 2.3271(7); C(1)-P(1)-C(6), 92.65(14); 
Cl(1)-Pd(1)-P(1)-C(9), 72.16(11); C(9)-P(1)-P(1A)-C(9A), 180.0. 6b: Pd(1)-Cl(1), 2.3055(4); 
Pd(1)-Cl(2), 2.3112(4); Pd(1)-P(1), 2.3234(4); Pd(1)-P(2), 2.3263(4); C(1)-P(1)-C(4), 93.29(7); 
C(13)-P(1)-C(16), 93.03(7); Cl(1)-Pd(1)-P(1)-C(9), -110.73(6); Cl(2)-Pd(1)-P(2)-C(21), -
58.41(6); C(9)-P(1)-P(2)-C(21), 10.68(8). 
One striking feature of the 31P NMR spectra for the trans-[MCl2(PhobPBu)2] complexes, the 
data for which are presented in Table 2, is that the ambient temperature spectra of some of the 
complexes show two sharp singlets at similar chemical shifts which coalesce at higher 
temperatures. Moreover, in the cases where one singlet was observed at room temperature, the 
low temperature 31P NMR spectra also showed two singlets. This indicates that the complexes 
generally exist in two forms which (from the observed ratios of between 3:1 and 1:1) are close in 
energy and interconvert on the NMR timescale with coalescence temperatures ranging from -100 
˚C to over + 100 ˚C, which translates12 into free energies of activation ΔG‡ of 8 to >19 kcal mol-1 
(see Table 2). It is proposed that the fluxionality is due to interconversion of two rotamers 
(Scheme 2) by slow rotation around the Pt–P bond; one of the rotamers has C2h-symmetry with 
the R groups of the PhobPR ligands anti to each other (as in the crystal structures of 1-4a) and the 
second rotamer has C2v-symmetry with the R groups syn to each other (as in the crystal structures 
of 3b and 6b).  
The restricted M–P rotation hypothesis is supported by DFT calculations (B3LYP/6-31G* and 
LACV3P on Pt) on the isomeric complexes trans-[PtCl2(s-PhobPBu)2] (1a and 1b), which 
revealed two energy minima at torsion angles φ(C-P-P-C) = 168° and 338° for the quasi C2h and 
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C2v conformations respectively for 1a, and φ(C-P-P-C) = 141° and 319° for 1b. The rotation 
profiles were computed by rotating one phosphine about its Pt–P bond in 30° increments, 
showing a barrier to rotation between the two minima of 9.7 kcal mol-1 for 1a and 15.2 kcal mol-1 
for 1b (see Figure 3). Despite the simplicity of these gas-phase calculations that take no account 
of solvation and dispersion effects,13 these calculated values are close to the NMR-determined 


















Figure 4. Pt–P rotation profiles for trans-[PtCl2(s-PhobPR)2] in kcal mol-1 relative to the energy 
minimum (at φ = 344°for 1a, and 141° for 1b). Complex legend: red = 1a (R = nBu); black = 1b 
(R = iBu). 
From the energy barriers to M–P rotation obtained by NMR spectroscopy and given in Table 2, 
the following observations can be made. (1) The barriers for the trans-[PtCl2(s-PhobPBu)2] (1a–
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d) increase in the order nBu < sBu ~ iBu < tBu. (2) The barriers are consistently 3-4 kcal mol-1 
higher for the complexes of PhobPiBu (1–6b) than for the analogous complexes of PhobPnBu (1–
6a). (3) The values for the bicyclic diastereoisomers of trans-[MCl2(PhobPBu)2] are in the order 
a5 ≥ s > a7. (4) The values are similar for analogous Pt and Pd complexes. All four observations 
are consistent with steric effects controlling the size of the barrier – the larger the tertiary 
phobane, the higher the barrier (trends (1) – (3)) and the similar radii of Pt and Pd leads to similar 
barriers. 
Restricted M–P rotation in trans square planar complexes has been previously observed with 
bulky phosphine ligands or when the ligands cis to the PR3 are bulky.5-7 Shaw et al. reported5 
NMR evidence for restricted rotation in trans-[PtCl2(RPtBu2)2] (R = H, Me, Et, nPr, CCPh) 
amounting to barriers in the range 8-15 kcal mol-1 and associated this with the bulk of the PtBu2 
group. However in our systems, neither the PhobP group nor the adjacent Cl ligands can be 
described as especially bulky using traditional measures of steric hindrance; the averaged 
crystallographic cone angle for PhobP from the above structures is 107˚ which can be compared 
with 115˚ for PiPr2 in trans-[PdCl2{PiPr2(CH2CH2CH2CN)}2].14 Restricted M–P rotation has 
also been noted in the complex [RuCl2(=CHR)(s-PhobPCy)2] but not detected in ostensibly 
similar complexes such as [RuCl2(=CHR)(PPhCy2)2].15 The observation of restricted rotation of 
the PhobPR ligands at ambient temperatures therefore appears to be atypical and this prompted us 
to explore this observation further using computational methods. 
Computational Study of Energy Barriers to M–P rotations. The model chosen to probe the 
barrier to M–P rotation was the d8, square planar, anionic species [PdCl3(R’2PR)]– (where R’2P = 
tBu2P or PhobP) in which the ligands cis and trans to the phosphine remain constant. By rotating 
the PdCl3 fragment about the Pd–P bond, an energy profile for each phosphine can be obtained. 
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The calculated rotation curves for the [PdCl3(tBu2PR)]– complexes (Chart 4) are shown in 
Figure 5(a) where the energy is plotted against the Cl–Pd–P–R torsion angle. It is clear that the 
peaks occur at 90˚/270˚ and the troughs at 0˚/180˚. The computed structures for the conformers of 
[PdCl3(tBu2PCH3)]– at the turning points in the curve are shown in Figure 5(b). For the high 
energy 90˚ conformer there is a close approach (averaging 2.5 Å) of four of the H atoms of the t-
butyl substituents to the adjacent Cl atoms but no close interactions with the methyl substituent; 
by extrapolation, the bulk of the R substituent should not significantly affect the energy of the 90˚ 
conformer of [PdCl3(tBu2PR)]–. In the low energy 0˚ conformer, three H....Cl interactions 
(averaging 2.7 Å) are identified, one of which involves the P–CH3 substituent; by extrapolation, 
the more bulky the R substituent, the higher the energy of the 0˚ conformer of [PdCl3(tBu2PR)]– 
should become which would have the effect of compressing the barrier to rotation. Thus the 
energy barrier to Pd–P rotation in [PdCl3(tBu2PR)]– is inversely correlated with the steric bulk of 
the R group, rising in the order tBu < iPr < Me < H. This is consistent with the reported highly 
















Figure 5. (a) Pd–P rotation profiles in kcal mol-1 relative to the energy minimum for complexes 
A–D (see Chart 4). Projections shown are looking down the P–Pd bond for the 90˚ / 270˚ and 0˚ / 
180˚ conformers. (b) Calculated structures for the 90˚ and 0˚ conformers of [PdCl3(PMetBu2)]- 
with the closest Cl.....H distances (in Å) annotated. 
 The calculated Pd–P rotation curves for the [PdCl3(s-PhobPR)]– complexes (Chart 5) are 
shown in Figure 6(a) and it is apparent that the barrier to rotation increases with increasing bulk 
of the R group rising in the order H < Me < nBu < sBu < iBu < tBu. This parallels the order of the 
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barriers to rotation observed experimentally by NMR for the trans-[MCl2(PhobPBu)2] complexes 
(Table 2). In Figure 6(b), the calculated Pd–P rotation curves for the diastereoisomers of 
[PdCl3(PhobPnBu)]– are shown and the observed trend in barriers to rotation of a5 ≥ s > a7 is also 
the same as that observed experimentally for the diastereoisomers of trans-[MCl2(PhobPnBu)2] 
complexes (Table 2). The minima in the curves occur when the Pd–Cl and P–R are 
approximately orthogonal (80-110˚) which is the conformation observed in all ten of the crystal 
structures of the trans-[MCl2(PhobPBu)2] complexes described above. The results displayed in 
Figure 6 show that the DFT calculations on the model complex [PdCl3(PhobPR)]– faithfully 

























 Figure 6. Pd–P rotation profiles in kcal mol-1 relative to the energy minimum for complexes I–
VI (see Chart 5).  
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Scrutiny of the curves of Figure 6 shows that the minima consistently occur at Cl–Pd–P–R 
torsion angles in the vicinity of 90˚ and 270˚ but the maxima occur in two regions: at 0˚/180˚ for 
R = H, CH3, sBu or tBu and at 150˚/330˚ (i.e. 150˚/-30˚) for R = nBu, iBu. These observations can 
be rationalized qualitatively in terms of steric interactions between H atoms on the phobane 
ligands and the adjacent M–Cl. In the low energy, 90˚ conformer of [PdCl3(s-PhobPCH3)]– shown 
in Figure 7(a), there are no short (< 3.0 Å) H…..Cl contacts identified and it can be inferred that 
the bulk of the R substituent would not significantly affect the energy of the 90˚ conformer. In the 
high energy 0˚ conformer (Figure 7(b)), there are two short 1,3-diaxial H….Cl contacts (< 2.6 Å) 
across the chair-like phosphacycle between a Pd–Cl and two C–H groups and there are two 
H….Cl contacts (< 2.9 Å) between the P–CH3 with an Pd–Cl. The repulsive interactions 
identified in the 0˚ conformer of [PdCl3(s-PhobPCH3)]– would be expected to increase for 
[PdCl3(s-PhobPR)]– if the bulk of R were greater than CH3 and this would produce an increased 
barrier to rotation. Thus the high rotational barrier of ca. 21 kcal mol-1 calculated for [PdCl3(s-
PhobPtBu)]– is understandable in terms of the very close contacts between the Pd–Cl groups and 
two of the β-hydrogens of the t-butyl group and 1,3-diaxial hydrogens of the phosphacycle in the 
































Figure 7. Computed structures of [PdCl3(PhobPR)]– with the close Cl.....H distances (in Å) 
annotated for (a) φ = 90°/270˚, R = Me; (b) φ = 0°/180˚, R = Me; (c) φ = 0°/180˚, R = tBu. 
It is more difficult to be definitive about the steric interactions that determine the Pd–P rotation 
profiles for other s-PhobPR ligands because these will depend on the conformation of the chain 
in the substituent R group which can potentially adopt several conformations of similar energy; 
for example, the nBu chain adopts three different conformations in the diastereoisomers of 
PhobP(=Se)nBu (see Figure 1). Nevertheless, it is instructive to examine the source of the large 
calculated rotational barriers for [PdCl3(s-PhobPR)]– of 12 (R = nBu) and 17 (R = iBu) kcal mol-1 
and the 30˚ shift in the position of the energy maxima relative to [PdCl3(s-PhobPMe)]– (see 
Figure 6(a). The complex [PdCl3(s-PhobPiBu)]– was selected for further study because the 
conformational analysis for the PCH2CH(CH3)2 substituent is relatively simple. For the favored 
conformation of the isobutyl substituent, a Cl–Pd–P–C of 0˚ produces Pd–Cl interactions with an 
H atom on each of the α-C and β-C of the isobutyl group in addition to interactions with two 
axial H atoms in the phosphacycle (Figure 8(a)). Rotation of the PdCl3 through 30˚ produces two 
very short H....Cl contacts (< 2.4 Å): one with a β-C–H of the isobutyl group and the other with 
an axial C–H in the bicycle (Figure 8(b)). It is the repulsive energy of these interactions that is 
the likely explanation for the 30˚ translocation and the higher energy of the peaks in the rotation 
profile for [PdCl3(s-PhobPiBu)]– relative to those for [PdCl3(s-PhobPMe)]–. It therefore appears 
 
20 
that the Pd–Cl interaction with the β-C–H is greater than with the α-C–H in these complexes. 






















(a) (b)  
Figure 8. Computed structures of [PdCl3(PhobPiBu)]– with the close Cl.....H distances (in Å) 
annotated when (a) φ = 0°/180˚; (b) φ = 150˚/330° (–30˚). 
The central inference from the DFT conformational studies is that the rigidity of the bicycle in 
the PhobPR ligands leads to unavoidable clashes between axial H atoms in the bicycle and the cis 
Cl ligands resulting in high barriers to M–P rotation. The barriers to M–P rotation in the PhobPR 




Prior to this work, restricted M–P rotation had been identified as an important characteristic of 
the coordination chemistry of tBu2PR ligands.6 Complexes of tBu2PR ligands have found 
widespread applications in homogeneous catalysis ranging from C–X coupling reactions7,16 to 
ethene methoxycarbonylation.17 The conformational rigidity of tBu2PR complexes partly explains 
their facility to undergo cyclometallation,6 and this feature has been exploited notably in the 
burgeoning area of pincer complexes derived from ligands featuring tBu2P groups.18 Here we 
have shown that complexes of the bicyclic phosphines PhobPR, which are not deemed to be 
bulky, also exhibit restricted M–P rotation.  
From NMR measurements on trans-[MCl2(R’2PR)2] (M = Pd, Pt; R’2P = tBu2P or PhobP) and 
computational studies on the model complexes [PdCl3(R’PR2)]–, the barriers to rotation depend 
on the bulk of substituent R. However the trend in the energy barriers depends on R’2P: for 
tBu2PR complexes, the barrier increases with decreasing size of R but for PhobPR the barrier 
increases with increasing size of R (see Figure 9(a)). The corollary of these trends is that the 
barriers to M–P rotation for square planar complexes with trans tBu2PR ligands reach a natural 
maximum for R = H whereas the barrier for the analogous PhobPR complexes does not have such 
a limitation. This releases scope for the design of PhobPR ligands whose complexes may have 
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Figure 9. (a) Calculated barriers to M–P rotation as a function of R substituent in the model 
complexes [PdCl3(R’2PR)2]– where R’2P = tBu2P (red) or PhobP (black). (b) Schematic 
representation of the conformer energies for the complexes [R’2PR–PdCl3]– where R’2P = PhobP 
and tBu2P. 
The diagram in Figure 9(b) can be used to explain succinctly the contrasting effects the bulk of 
the R groups have on the barrier to Pd–P rotation in the square planar complexes [R’2PR–PdCl3]– 
where R’2P = PhobP and tBu2P. For all of the complexes of tBu2PR and most of the complexes of 
PhobPR, the R group will have its greatest effect on the energy when the P–R eclipses the Pd–Cl 
(the 0˚ conformer) ranging from R = H (lowest) to R = tBu in Figure 9(b). When the P–R is 
orthogonal to the Pd–Cl (the 90˚ conformer), the effect of the R group will be negligible. For the 
tBu2PR complexes, the energy is dominated by the repulsive interactions of Pd–Cl with the two 
bulky tBu substituents which are a maximum for the 90˚ conformer and therefore, as is clear from 
Figure 9(b), the greater the bulk of R, the more compressed the energy separation is between the 
rotamers. By contrast, for the PhobPR complexes, the energy is a function of the repulsive 1,3-
diaxial interactions of Pd–Cl with the phosphacycle C–H groups (see above) which are a 
 
23 
minimum for the 90˚ conformer and therefore, as is clear from Figure 9(b), the greater the bulk of 
R, the greater the energy separation is between the rotamers. These conclusions should be general 
for square planar complexes of PhobPR ligands. 
The rigidity (or preoganisation) of coordinated tBu2PR ligands has well-documented 
consequences for the chemistry of their complexes and may well be a component in the success 
of tBu2PR ligands in catalysis. The ramifications of the high rigidity of coordinated PhobPR 
ligands for their chemistry are currently under investigation.  
Experimental 
General considerations. Unless otherwise stated, all work was carried out under a dry 
nitrogen atmosphere, using standard Schlenk line techniques. Dry N2-saturated solvents were 
collected from a Grubbs system19 in flame and vacuum dried glassware. The complexes 
[PtCl2(NCtBu)2]20 and [PdCl2(NCPh)2]21 were made by literature methods. Isomeric mixtures of 
phobanes were obtained from Shell or Rhodia and the following phobanes were made by our 
previously published methods:1 s-PhobPCl, s-PhobPnBu, a5-PhobPnBu, a7-PhobPnBu. All other 
chemicals were purchased from Aldrich. NMR spectra were measured on a Jeol ECP 300, 
Lambda 300, ECP 400 or Varian 400. Unless otherwise stated, 1H, 13C, 31P and 19F NMR spectra 
were recorded at 400, 100, 121 and 282 MHz respectively at +23 ˚C. Mass spectra were recorded 
on a VG Analytical Autospec or Bruker Daltonics Apex IV spectrometer. Elemental analyses 
were carried out by the Microanalytical Laboratory of the School of Chemistry, University of 
Bristol. 
Preparation of s-PhobPBr. Pure s-PhobPH (5.00 g, 35.2 mmol) was dissolved in CH2Cl2 (50 
cm3). A solution of Br2 (1.81 cm3, 35.2 mmol) in CH2Cl2 (50 cm3) was added at 0 ºC over 2 h. 
The solution was filtered and the solvent was removed under reduced pressure to give s-PhobPBr 
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(6.20 g, 28.0 mmol, 80%). The product was then redissolved in toluene (50 cm3) and used as a 
stock solution (0.56 M). 31P NMR (C6D6): δP 91.4. 13C NMR (CDCl3): δC 31.3 (d, JPC 17.1 Hz), 
29.7 (d, JPC 31.1 Hz), 25.3 (d, JPC 3.9 Hz), 22.5 (d, JPC 3.1 Hz), 21.3 (s). 1H NMR (CDCl3): δH 
2.65 (2H, br s), 2.51 (2H, br s), 2.20 (4H, br m), 2.09-1.60 (6H, m), 1.57 (1H, m), 1.42 (1H, m). 
HRMS (EI): calcd. for C8H14BrP: 220.0017, found, 220.0009. 
Preparation of s/a-mixture of PhobPBr. The phobane mixture (10 cm3 in toluene) was 
concentrated under reduced pressure and the resultant PhobPH (7.20 g, 52.0 mmol) was then 
dissolved in CH2Cl2 (100 cm3). A solution of Br2 (3.0 cm3, 58 mmol) in CH2Cl2 (100 cm3) was 
added at 0 ºC over 3.5 h. The reaction was monitored by 31P NMR spectroscopy which showed 
how the starting material PhobPH was converted to PhobPBr through several intermediate 
species. When the reaction was complete, some white solid, probably PhobPBr3, had precipitated 
from solution (< 0.2 g). The solution was filtered and the solvent was removed under reduced 
pressure to give PhobPBr (9.00 g, 40.7 mmol, 78%). The product was redissolved in hexane or 
toluene and used as a stock solution or further purified by distillation (74-76 ºC at 0.41 mmHg) 
affording a clear liquid. 31P NMR (C6D6): δP s 91.4, a 130.0. 
Preparation of s-PhobPiBu. Pure s-PhobPH (0.70 g, 4.9 mmol) was dissolved in hexane (10 
cm3) and the solution cooled to 0 °C. A solution of nBuLi (3.4 cm3, 1.6 M in hexane, 5.4 mmol) 
was added dropwise over 5 min and then immediately afterwards, the solution was cooled to -78 
°C and 1-bromo-2-methylpropane (0.53 cm3, 4.9 mmol) was added dropwise over 10 min. The 
reaction mixture was allowed to warm to room temperature and stirred for 20 h. The solvent was 
then removed under reduced pressure and the residue was suspended in deoxygenated water (10 
cm3) and extracted with hexane (3 x 10 cm3). The combined organic layers were dried over 
MgSO4, filtered, the solvent removed under reduced pressure and the resultant product distilled 
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(76-78 °C at 0.56 mmHg) to give s-PhobPiBu as a clear liquid. Yield: 0.39 g (2.0 mmol, 40%). 
31P NMR (C6D6): δP, -39.3. 13C NMR (C6D6): δC, 32.0 (d, JPC 23.4 Hz), 31.4 (d, JPC 12.5 Hz), 26.0 
(d, JPC 18.7 Hz), (d, JPC 11.5 Hz), 23.9 (d, JPC 10.9 Hz), 23.6 (d, JPC 3.9 Hz), 23.2 (d, JPC 9.3 Hz), 
22.7 (d, JPC 5.4 Hz), 20.9 (d, JPC 1.6 Hz). 1H NMR (C6D6): δH, 1.99-1.50 (10H, m), 1.39 (5H, br s), 
1.19 (2H, d), 0.81 (6H, d). HRMS (EI): calcd. for C12H23P: 198.1537, found, 198.1534. 
Preparation of a5-PhobPiBu. Pure a-PhobPH (3.00 g, 21.1 mmol) was dissolved in THF (25 
cm3) and the solution cooled to 0 °C. A solution of nBuLi (14.5 cm3, 1.6M in hexane, 23.2 mmol) 
was added dropwise over 15 min. The solution was stirred for 30 min and then cooled to -78 °C. 
1-bromo-2-methylpropane (2.29 cm3, 21.1 mmol) was added dropwise over 5 min and the 
reaction mixture was allowed to warm to room temperature and then stirred for a further 2.5 h. 
The solvent was then removed under reduced pressure. The residue was suspended in water (40 
cm3) and then extracted with hexane (4 x 40 cm3). The combined organic layers were dried over 
MgSO4. The solvent was removed under reduced pressure and the liquid product was distilled 
(120 °C at 1.3 mmHg) to give a5-PhobPiBu as a clear liquid. Yield: 3.50 g (17.6 mmol, 84%, 
containing 4% a7-PhobPiBu). 31P{1H} NMR (C6D6): δP -3.16. 13C{1H} NMR (CD2Cl2): δC 40.0 (d, 
JPC 12.5 Hz), 35.3 (d, JPC 15.6 Hz), 34.6 (d, JPC 18.7 Hz), 33.9 (d, JPC 6.23 Hz), 33.2 (d, JPC 5.45), 
27.3 (d, JPC 16.4 Hz), 25.6 (s), 25.6 (s), 24.0 (d, JPC 9.34 Hz). 1H NMR (CD2Cl2): δH 2.19-2.06 
(4H, m), 1.81-1.67 (2H, m), 1.66-1.60 (3H, br m), 1.50-1.28 (7H, br m), 1.02 (2H, dd), 0.96 (6H, 
d). Anal. Calcd for C12H23P: C, 72.69; H, 11.69. Found C, 72.26 ; H, 11.26 MS (EI): m/z 199.1 
(M)+. 
Preparation of a7-PhobPiBu. Pure a-PhobPH (2.00 g, 14.1 mmol) and 1-bromo-2-
methylpropane (3.26 cm3, 30 mmol) were dissolved in MeCN (5 cm3) and the reaction mixture 
was heated to reflux for 96 h. The solvent was then removed under reduced pressure and the 
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resultant colorless precipitate suspended in diethyl ether (20 cm3) and NaOH (15.5 cm3 of a 1M 
aqueous solution, 15.5 mmol) was added. The reaction mixture was stirred for 30 min after which 
the two phases were separated. The aqueous phase was extracted with diethyl ether (3 x 20 cm3). 
The combined washings were dried over MgSO4, filtered and then concentrated under reduced 
pressure. The liquid product was distilled (140 °C at 1.3 mmHg) to give a7-PhobPiBu as a clear 
liquid. Yield: 1.00 g (5.05 mmol, 36%, containing 8% a5-PhobPiBu). 31P{1H} NMR (C6D6): δP -
4.11. 13C{1H} NMR (CD2Cl2): δC 40.0 (d, JPC 12.5 Hz), 34.5 (d, JPC 10.9 Hz), 33.2 (d, JPC 5.45 
Hz), 30.7 (d, JPC 20.2 Hz), 29.7 (d, JPC 27.3 Hz), 28.8 (d, JPC 22.6 Hz), 25.7 (s), 23.7 (d, JPC 10.1 
Hz). 1H NMR (CD2Cl2): δH 2.33 (2H, br d), 2.04 (2H, br m), 1.80 (2H, m), 1.66 (4H, br m), 1.52 
(2H, m), 1.39 (5H, br m), 0.99 (6H, d). Anal. Calcd for C12H23P: C, 72.69; H, 11.69. Found C, 
72.92 ; H, 11.42. MS (EI): m/z 199.1 (M)+. 
Preparation of s/a-mixture of PhobPiBu. The phobane mixture (24 cm3 in toluene) was 
concentrated under reduced pressure to give solid PhobPH (16.0 g, 113 mmol). This was 
dissolved in THF (75 cm3) and then cooled to 0 °C. A solution of nBuLi (77.5 cm3, 1.6M in 
hexane, 124 mmol) was added dropwise over 30 min and then immediately after this addition the 
reaction mixture was cooled to -78 °C and 1-bromo-2-methylpropane (12.3 cm3, 113 mmol) was 
added dropwise over 15 min. The reaction mixture was allowed to warm to room temperature and 
then stirred for a further 20 h. The solvent was removed under reduced pressure and the residue 
was suspended in deoxygenated water (40 cm3) and then extracted with hexane (3 x 40 cm3). The 
combined organic layers were dried over MgSO4, filtered and the solvent was removed under 
reduced pressure. The resulting product was distilled (96-98 °C at 1.4 mmHg) to give a clear 
liquid. Yield: 14.2 g (71.7 mmol, 64%; ratio of isomers: 61% s, 39% a5). 31P NMR (121 MHz, 
C6D6): δP s -39.3; a5 -3.0; a7 not observed. 
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Preparation of s-PhobPsBu. Pure s-PhobPH (1.00 g, 7.00 mmol) was dissolved in THF (10 
cm3) and then cooled to 0 °C. A solution of nBuLi (4.85 cm3, 1.6 M in hexane, 7.70 mmol) was 
added dropwise over 5 min. The solution was stirred for 20 min and then cooled to -78 °C. 2-
Bromobutane (0.77 cm3, 7.0 mmol) was added dropwise over 5 min and the reaction mixture was 
allowed to warm to room temperature and then stirred for a further 20 h. The solvent was 
removed under reduced pressure and the residue was suspended in deoxygenated water (10 cm3) 
and then extracted with hexane (3 x 10 cm3). The combined organic layers were dried over 
MgSO4, filtered and the solvent was removed under reduced pressure. The resulting product was 
distilled (74-76 °C at 0.45 mmHg) to give s-PhobPsBu as a clear liquid. Yield: 0.30 g (1.5 mmol, 
21%). 31P NMR (C6D6): δP, -23.8. 13C NMR (C6D6): δC, 32.5 (d, JPC 12.3 Hz), 32.3 (d, JPC 11.5 
Hz), 26.7 (d, JPC 18.5 Hz), 25.4 (d, JPC 19.2 Hz), 24.9 (d, JPC 3.8 Hz), 24.5 (d, JPC 3.8 Hz), 23.8 (d, 
JPC 5.4 Hz), 23.5 (d, JPC 28.4 Hz), 23.3 (d, JPC 28.4 Hz), 21.9 (d, JPC 1.5 Hz), 14.0 (d, JPC 18.5 Hz), 
11.7 (d, JPC 10.8 Hz). 1H NMR (C6D6): δH, 2.22-2.07 (2H, m), 2.02-1.75 (8H, m), 1.72 (1H, br s), 
1.62-1.42 (5H, m), 1.33-1.21 (1H, m), 0.98 (3H, dd, JPH 14 Hz, JHH 7.3 Hz), 0.95 (3H, t). HRMS 
(EI): calcd. for C12H23P: 198.1537, found, 198.1531. 
Preparation of s/a-mixture of PhobPsBu. The phobane mixture (30 cm3 in toluene) was 
concentrated under reduced pressure to give PhobPH (20.0 g, 141 mmol). This was dissolved in 
THF (120 cm3) and then cooled to 0 °C. A solution of nBuLi (97.0 cm3, 1.6 M in hexane, 155 
mmol) was added dropwise over 30 min. Once the addition was complete, the mixture was 
cooled to -78 °C and 2-bromobutane (15.4 cm3, 141 mmol) was added dropwise over 15 min. The 
reaction mixture was allowed to warm to room temperature and then stirred for 15 h. The solvent 
was removed under reduced pressure and the residue was suspended in deoxygenated water (100 
cm3) and then extracted with hexane (3 x 100 cm3). The combined extracts were dried over 
MgSO4, filtered and the solvent was removed under reduced pressure. The resulting product was 
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distilled (102-104 °C at 1.9 mmHg) to give a clear liquid: Yield: 12.0 g (43%; ratio of isomers: 
65% s, 35% a5). 31P NMR (C6D6): δP, s -23.8; a5 14.5; a7 not observed. 
Preparation of s-PhobP-(R)-sBu  
Pure s-PhobPH (13.0 g, 91.5 mmol) was dissolved in THF (15 cm3) and the solution cooled to 
0 °C. BH3.THF (10.5 cm3, 1 M in THF, 10.5 mmol) was added dropwise over 10 min and the 
mixture stirred at 0 °C for 30 min. A solution of nBuLi (6.59 cm3, 1.6 M in hexane, 10.5 mmol) 
was added dropwise over 10 min. The mixture was stirred for a further 10 min and then cooled to 
-78 °C. (S)-(+)-2-butyl tosylate22 (1.61 g, 7.03 mmol) in THF (10 cm3) was added dropwise over 5 
min and the reaction mixture was allowed to warm to room temperature and stirred for a further 3 
h. The solvent was removed under reduced pressure and then pyrrolidine (15 mL) was added and 
the mixture stirred for 16 h. The pyrrolidine was then removed under reduced pressure and the 
residue was suspended in water (40 cm3) and then extracted with hexane (4 x 40 mL). The 
combined organic layers were dried over MgSO4. The solvent was removed under reduced 
pressure and the liquid residue was distilled (120 °C at 1.3 mmHg) to give s-PhobPsBu as a clear 
liquid. Yield: 3.37 g (17.0 mmol, 81%). 31P{1H} NMR (121 MHz, C6D6): δP -24.2. 1H NMR (400 
MHz, C6D6): δH 2.22-2.07 (2H, m), 2.02-1.75 (8H, m), 1.72 (1H, br s), 1.62-1.42 (5H, m), 1.33-
1.21 (1H, m), 0.98 (3H, dd, JPH 14.0 Hz, JHH 7.3 Hz), 0.95 (3H, t, JHH 14.2 Hz). 13C{1H} NMR 
(100 MHz, C6D6): δC 32.5 (d, JPC 12.3 Hz), 32.3 (d, JPC 11.5 Hz), 26.7 (d, JPC 18.5 Hz), 25.4 (d, JPC 
19.2 Hz), 24.9 (d, JPC 3.8 Hz), 24.5 (d, JPC 3.8 Hz), 23.8 (d, JPC 5.4 Hz), 23.5 (d, JPC 28.4 Hz), 23.3 
(d, JPC 28.4 Hz), 21.9 (d, JPC 1.5 Hz), 14.0 (d, JPC 18.5 Hz), 11.7 (d, JPC 10.8 Hz). Anal. Calcd for 
C12H23P: C, 72.69; H, 11.69. Found C, 72.42; H, 11.33. 
Preparation of s-PhobPtBu. A solution of tert-butylmagnesium chloride (5.0 cm3, 1.0M in 
THF, 5.0 mmol) was added dropwise over 10 min at 60 °C to a solution of pure s-PhobPBr (1.00 
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g, 4.50 mmol) in toluene (10 cm3) and the mixture stirred for 3 h. The solvent was removed under 
reduced pressure and a saturated aqueous solution of NH4Cl (10 cm3) was added to it, followed 
by extraction with hexane (3 x 10 cm3). The combined organic layers were dried over MgSO4, 
filtered and the solvent was removed under reduced pressure. The resulting product was distilled 
(71-73 °C at 0.44 mmHg) to give s-PhobPtBu as a clear liquid. Yield: 0.10 g (0.50 mmol, 11%). 
31P NMR (C6D6): δP, -3.7. 13C NMR (C6D6): δC, 34.6 (d, JPC 15.4 Hz), 30.3 (d, JPC 16.1 Hz), 29.3 
(d, JPC 13.1 Hz), 25.4 (d, JPC 3.8 Hz), 24.9 (d, JPC 19.2 Hz), 23.8 (d, JPC 5.4 Hz), 21.6 (s). 1H NMR 
(C6D6): δH, 2.36-2.08 (4H, m), 2.02-1.81 (6H, m), 1.62-1.51 (4H, m), 1.15 (9H, d, JPH 12 Hz). MS 
(EI): m/z = 215 (M + O). 
Preparation of s/a-mixture of PhobPtBu. A solution of tert-butylmagnesium chloride (88 
cm3, 0.5M in THF, 44 mmol) was added dropwise over 30 min at 60 °C to a solution of s/a-
PhobPBr (9.0 g, 40 mmol) in toluene (55 cm3) and the mixture stirred for 3 h. After 45 min, the 
31P{1H} NMR spectrum showed a mixture of desired product (30%) and PhobP-PPhob23 (60%). 
The solvent was removed under reduced pressure and then a saturated aqueous solution of NH4Cl 
(30 cm3) was added to the residue, followed by extraction with hexane (3 x 30 cm3). The 
combined organic layers were dried over MgSO4, filtered and the solvent was removed under 
reduced pressure. The resulting product was distilled (76-78 °C at 0.84 mmHg) to give a clear 
liquid. Yield: 1.00 g (5.05 mmol, 13%; ratio of isomers: 64% s, 8% a7, 28% a5). 31P NMR (C6D6): 
δP, s -3.7; a7 27.2; a5 33.4. 
Preparation of isomers of PhobP(=Se)nBu. Pure s-, a5- or a7-isomer of PhobPnBu (0.049 g, 
0.25 mmol) was placed in an NMR tube under N2 and then KSeCN (0.070 g, 0.50 mmol) in 
MeOH (0.7 cm3) was added and the tube shaken a few times. The reactions were complete after 
10 min (as shown by 31P NMR spectroscopy). The solvent was removed under reduced pressure 
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and the solid residue was extracted with CHCl3 (2 x 0.5 cm3). Slow evaporation of the chloroform 
gave the desired compounds as white crystalline solids. s-PhobP(=Se)nBu: 31P NMR (MeOH): 
δP, 37.2 (s, JPSe 671 Hz); (CDCl3): δP, 35.4 (s, JPSe 684 Hz). 13C NMR (CDCl3): δC, 30.4 (d, JPC 36.6 
Hz), 27.7 (d, JPC 4.7 Hz), 27.1 (d, JPC 2.3 Hz), 26.3 (d, JPC 42.8 Hz), 24.2 (d, JPC 3.1 Hz), 23.8 (d, 
JPC 15.6 Hz), 21.7 (d, JPC 6.2 Hz), 20.5 (d, JPC 6.2 Hz), 13.8 (s). 1H NMR (CDCl3): δH, 2.93-2.79 
(2H, br m), 2.23-1.66 (16H, m), 1.53-1.44 (2H, m), 0.97 (3H, t). MS (EI): m/z, 278.1 (M+). a7-
PhobP(=Se)nBu: 31P NMR (MeOH): δP, 60.7 (s, JPSe 649 Hz); (CDCl3): δP, 58.8 (s, JPSe 662 Hz). 
13C NMR (CDCl3): δC, 42.4 (d, JPC 38.4 Hz), 30.6 (d, JPC 3.1 Hz), 28.6 (d, JPC 12.3 Hz), 26.9 (d, JPC 
32.3 Hz), 26.2 (d, JPC 3.1 Hz), 24.8 (s), 23.9 (d, JPC 14.6 Hz), 13.9 (s). 1H NMR (CDCl3): δH, 2.82-
2.69 (2H, br m), 2.66-2.56 (2H, br m), 2.27-2.18 (2H, m), 1.90-1.56 (12H, m), 1.54-1.46 (2H, m), 
0.96 (3H, t). MS (EI): m/z, 278.1 (M+). a5-PhobP(=Se)nBu: 31P NMR (MeOH): δP, 60.7 (s, JPSe 
696 Hz); (CDCl3): δP, 59.4 (s, JPse 707 Hz). 13C NMR (CDCl3): δC, 36.8 (d, JPC 36.8 Hz), 30.6 (d, 
JPC 39.9 Hz), 30.5 (s), 28.6 (d, JPC 11.5 Hz), 25.3 (d, JPC 2.3 Hz), 24.1 (d, JPC 2.3 Hz), 23.9 (d, JPC 
14.6 Hz), 13.8 (s). 1H NMR (CDCl3): δH, 2.41-2.34 (2H, br m), 2.25-2.13 (6H, br m), 1.94-1.76 
(4H, m), 1.73-1.49 (6H, m), 1.44 (2H, m), 0.95 (3H, t, JHH 7.33 Hz). MS (EI): m/z, 278.1 (M+) 
General preparation of s-PhobP(Se)R. Pure s-PhobPR was placed in an NMR tube under N2. 
KSeCN (1 eq) in MeOH (0.5 cm3) was added and the NMR tube was shaken a few times. The 
reaction was generally complete within 10 min. The solvent was then removed under reduced 
pressure and the solid residues were extracted with chloroform. Filtration and evaporation of the 
chloroform gave the desired compound as white solids. Yields were quantitative. 
PhobP(=Se)iBu. PhobPiBu (0.069 g, 0.35 mmol), KSeCN (0.050 g, 0.35 mmol). 31P NMR 
(MeOH): δP, s 35.3 (s, JPSe 674 Hz); a5 58.4 (s, JPSe 700 Hz); (CDCl3): δP, s 35.0 (s, JPSe 679 Hz); 
a5 58.3 (s, JPSe 703 Hz). HRMS (EI): calcd. for C12H23PSe: 278.0703, found 278.0707. 
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PhobP(=Se)sBu. PhobPsBu (0.037 g, 0.19 mmol), KSeCN (0.027 g, 0.19 mmol). 31P NMR 
(MeOH): δP, s 48.4 (s, JPSe 679 Hz); a5 74.2 (s, JPSe 703 Hz); (CDCl3): δP, s 47.4 (s, JPSe 688 Hz); 
a5 73.4 (s, JPSe 712 Hz). HRMS (EI): calcd. for C12H23PSe: 278.0703, found, 278.0714. 
PhobP(=Se)tBu. PhobPtBu (0.039 g, 0.20 mmol), KSeCN (0.028 g, 0.20 mmol). 31P NMR 
(MeOH): δP, s 56.2 (s, JPSe 668 Hz); a7 81.8 (s, JPSe 621 Hz); a5 87.4 (s, JPSe 698 Hz); (CDCl3): δP, 
s 55.1 (s, JPSe 678 Hz); a7 80.5 (s, JPSe 648 Hz); a5 86.5 (s, JPSe 705 Hz). HRMS (EI) calcd. for 
C12H23PSe: 278.0703, found, 278.0709. 
General preparation of trans-[PtCl2(PhobPR)2] A solution of PhobPR (0.25 mmol) in 
CH2Cl2 (1.5 cm3) was added to a solution of [PtCl2(NCtBu)2] (50 mg, 0.12 mmol) in CH2Cl2 (1.5 
cm3). The mixture was stirred for 2 h, after which the solvent was removed under reduced 
pressure. The product was recrystallized from pentane to give pale yellow precipitates which 
were filtered off and dried under reduced pressure. Crystals were obtained by slow evaporation of 
CH2Cl2 solutions of the complexes.  
trans-[PtCl2(s-PhobPnBu)2] (1a). Yield: 0.078 g (0.12 mmol, 98%). 31P{1H} NMR (CD2Cl2): 
δP 4.1 (s, JPPt 2437 Hz). 13C{1H} NMR (CD2Cl2): δC 29.5 (s), 26.4 (s), 25.9 (s), 24.4 (t, JPC 12.3 
Hz), 22.4 (t, JPC 6.1 Hz), 21.4 (t, JPC 3.8 Hz), 21.4 (s), 20.8 (t, JPC 30.0 Hz), 13.6 (s). 1H NMR 
(CD2Cl2): δH 2.69-2.55 (4H, br m), 2.49 (2H, br m), 2.12-1.75 (24H, m), 1.69-1.48 (8H, m), 1.00-
0.93 (6H,t). Anal. Calcd for C24H46Cl2P2Pt: C, 43.51; H, 7.00. Found C, 43.68; H, 7.06. MS (ESI): 
m/z 685.20 (M+Na)+, 626.25 (M-Cl)+, 590.27 (M-2Cl)+. 
trans-[PtCl2(s-PhobPiBu)2] (1b). Yield: 0.060 g (0.09 mmol, 82%). 31P NMR (CD2Cl2): δP, 4.2 
(JPPt 2502 Hz), 3.1 (JPPt 2502 Hz). 13C NMR (CD2Cl2): δC, 30.2 (br s), 30.0 (br s), 27.0 (s), 25.1 
(br s), 24.9 (br s), 22.8 (s), 22.3 (br m), 21.9 (s). 1H NMR (CD2Cl2): δH, 2.61 (4H, br s), 2.43 (4H, 
br s), 2.12-1.49 (26H, m), 1.16 (6H, d), 1.05 (6H, d). MS (ESI): m/z = 590.26 (M+-2Cl). 
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trans-[PtCl2(s-PhobP-(R)-sBu)2] (1c). Yield: 0.066 g (0.10 mmol, 90%). 31P NMR (CD2Cl2): 
δP, 9.3 (JPPt 2493 Hz); 7.7 (JPPt 2614 Hz); the cis isomer (16%) was also detected in the spectrum: 
6.2 (JPPt 3352 Hz). Compound insufficiently soluble for 13C NMR. 1H NMR (CD2Cl2): δH, 2.67-
2.47 (br m), 2.36 (br s), 2.26-1.64 (m), 1.22-1.08 (br m). MS (ESI): m/z = 590.26 (M+-2Cl). 
trans-[PtCl2(s-PhobPtBu)2] (1d). Yield: 0.070 g (0.12 mmol, 93%). 31P NMR (CD2Cl2): δP, 
19.8 (JPPt 2231 Hz, major), 19.6 (JPPt 2231 Hz, minor). Ratio of isomers, 1.4:1. Compound 
insufficiently soluble for 13C NMR. 1H NMR (CD2Cl2): δH, 2.88 (2H, br s), 2.76 (2H, br s), 2.57-
1.93 (20H, m), 1.84 (4H, m) 1.53 (18H, t, JHH 7.7 Hz). MS (ESI): m/z, 590.26 (M-2Cl)+. 
trans-[PtCl2(a5-PhobPnBu)2] (2a). Yield: 0.073 g (0.11 mmol, 92%). 31P{1H} NMR (CD2Cl2): 
δP 40.7 (s, JPPt 2411 Hz). 13C{1H} NMR (CD2Cl2): δC 32.3 (t, JPC 30.4 Hz), 31.3 (s), 30.1 (t, JPC 7.0 
Hz), 26.4 (s), 24.7 (t, JPC 4.7 Hz), 23.5 (t, JPC 12.5 Hz), 23.4 (s), 12.8 (s). 1H NMR (CD2Cl2): δH 
2.66-2.61 (4H, br m), 2.33-2.24 (4H, br m), 2.20-2.09 (8H, m), 1.81-1.1.54 (12H, m), 1.51-1.34 
(12H, m), 0.86 (6H, t). Anal. Calcd for C24H46Cl2P2Pt: C, 43.51; H, 7.00. Found 43.55; H, 6.84. 
MS (ESI): m/z 685.21 (M+Na)+, 590.27 (M-2Cl)+.  
trans-[PtCl2(a5-PhobPiBu)2] (2b). Yield: 0.074 g (0.112 mmol, 89 %). 31P{1H} NMR (298 K, 
121 MHz, CD2Cl2): δP 38.4 (s, JPPt 2407 Hz), 37.8 (s, JPPt 2404 Hz). 31P{1H} NMR (373 K, 121 
MHz. C2H2Cl4): δP 38.6 (s, JPPt 2432 Hz). 13C{1H} NMR (400 MHz, CD2Cl2): δC 34.4 (t, JPC 15.0 
Hz), 33.8 (s), 32.2 (s), 31.0 (s), 27.6 (s), 26.3 (s), 25.5 (s), 24.5 (s). 1H NMR (400 MHz, CD2Cl2): 
δH 2.70 (4H, br s), 2.58-2.46 (2H, m), 2.44-2.31 (12H, br m), 2.30-2.09 (4H, br m), 1.79-1.66 
(4H, br m), 1.64-1.45 (8H, br m), 1.13 (6H, d), 1.10 (6H, d). Anal. Calcd for C24H46Cl2P2Pt: C, 
42.56; H, 7.00. Found C, 43.51; H, 6.56. MS (ESI): m/z 590.27 (M-2Cl)+.  
trans-[PtCl2(a7-PhobPnBu)2] (3a). Yield: 0.067 g (0.10 mmol, 85%). 31P{1H} NMR (CD2Cl2): 
δP 34.5 (s, JPPt 2311 Hz). 13C{1H} NMR (CD2Cl2): δC 36.5 (s), 31.0 (t, JPC 29.9 Hz), 29.4 (t, JPC 7.7 
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Hz), 28.5 (s), 25.2 (s), 24.0 (t, JPC 6.9 Hz), 19.7 (t, JPC 22.3 Hz), 13.7 (s). 1H NMR (CD2Cl2): δH 
3.13 (2H, s), 2.82-1.24 (38H, br m), 0.92 (6H, t). Anal. Calcd for C24H46Cl2P2Pt: C, 43.51; H, 
7.00. Found C, 43.44;H, 7.25. MS (ESI): m/z 685.21 (M+Na)+, 626.25 (M-Cl)+, 590.27 (M-2Cl)+. 
trans-[PtCl2(a7-PhobPiBu)2] (3b). Yield: 0.078 g (0.117 mmol, 93 %). 31P{1H} NMR (298, 
121 MHz, CD2Cl2): δP 31.6 (s, JPPt 2505 Hz). 31P{1H} NMR (173 K, 121 MHz, CH2Cl2): δP 33.7 
(s, JPPt 2261 Hz), 32.9 (s, JPPt 2255 Hz). 13C{1H} NMR (400 MHz, CD2Cl2): δC 31.9 (s), 31.7 (s), 
31.6 (s), 29.4 (t, JPC 7.50 Hz), 29.0 (s), 27.4 (s), 25.2 (s), 23.8 (s). 1H NMR (400 MHz, CD2Cl2): 
δH 3.11 (4H, s), 2.61-2.43 (2H, br m), 2.42-2.31 (5H, br m), 2.01-1.92 (5H, m), 1.92-1.72 (8H, br 
m), 1.71-1.43 (10H, br m), 1.10 (6H, d), 1.08 (6H, d). Anal. Calcd for C24H46Cl2P2Pt: C, 43.51; 
H. 7.00. Found 42.52; H, 6.78. MS (ESI): m/z 590.27 (M-2Cl)+. 
General preparation of trans-[PdCl2(PhobPR)2] A solution of a pure s-, a5- or a7-isomer of 
PhobPR (0.050 g, 0.25 mmol) in CH2Cl2 (2.0 cm3) was added to a solution of [PdCl2(NCPh)2] 
(0.048 g, 0.13 mmol) in CH2Cl2 (2.0 cm3). The mixture was stirred for 2 h after which the solvent 
was removed under reduced pressure. The products were recrystallized from pentane to give 
white precipitates which were filtered off and dried under reduced pressure.  
trans-[PdCl2(s-PhobPnBu)2] (4a). Yield: 0.0416 g (0.073 mmol, 58%). 31P{1H} NMR (298 K, 
121 MHz, CD2Cl2): δP 9.52 (s). 31P{1H} NMR (173 K, 121 MHz, CH2Cl2): δP 10.2 (s), 9.33 (s). 
13C{1H} NMR (500 MHz, CD2Cl2): δC 30.6 (s), 29.8 (s), 26.8 (t, JPC 1.91 Hz), 24.5 (s), 24.4 (s), 
22.52 (s), 22.4 (s), 22.3 (t, JPC 3.82 Hz), 21.4 (s), 21.2 (s), 18.0 (s), 13.6 (s). 1H NMR (500 MHz, 
CD2Cl2): δH 2.59-2.51 (8H, br m), 2.15 (8H, s), 2.11-1.84 (18H, br m), 1.55 (6H, s), 0.99 (6H, t). 
Anal Calcd for C26H46Cl2P2Pd:C, 50.23; H, 8.08. Found C, 50.51; H, 8.03. MS (ESI): m/z 537.18 
(M-Cl)+, 501.21 (M-2Cl).  
trans-[PdCl2(s-PhobPiBu)2] (4b). Yield: 0.0293 g (0.051 mmol, 41%). 31P{1H} NMR (298 K, 
121 MHz, CD2Cl2): δP 9.01 (s), 7.73 (s). 31P{1H} NMR (373 K, 121 MHz, C2H2Cl4): δP 7.68 (s). 
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13C{1H} NMR (500 MHz, CD2Cl2): δC 30.5 (br s), 29.9 (br s), 26.9 (s), 24.6 (br s), 23.4 (br s), 
22.1 (s), 21.2 (s), 20.3 (s). 1H NMR (400 MHz, CD2Cl2): δH 2.65-2.50 (10H, br m), 2.13-1.82 
(20H, br m), 1.66 (3H, t), 1.54 (1H, s), 1.22 (6H, d), 1.18 (6H, d). Anal Calcd for C26H46Cl2P2Pd: 
C, 50.23; H, 8.08. Found C, 50.61; H, 7.96. MS (ESI): m/z 501.20 (M-2Cl). 
trans-[PdCl2(a5-PhobPnBu)2] (5a). Yield: 0.0316 g (0.055 mmol, 44%). 31P{1H} NMR (298 K, 
121 MHz, CD2Cl2): δP 48.1. 31P{1H} NMR (193 K, 121 MHz, CH2Cl2): δP 48.2 (s), 48.0 (s). 
13C{1H} NMR (500 MHz, CD2Cl2): δC 34.3 (t, JPC 12.4 Hz), 32.4 (s), 30.6 (t, JPC 2.86 Hz), 27.8 
(br s), 25.8 (t, JPC 1.91 Hz), 24.50 (s), 24.45 (s), 24.40 (s), 24.1 (t, JPC 9.54 Hz), 13.5 (s). 1H NMR 
(500 MHz, CD2Cl2): δH 2.72 (4H, br s), 2.41 (4H, br s), 2.27-2.15 (8H, br m), 1.89-1.49 (18H, br 
m), 0.98 (6H, t). Anal. Calcd for C26H46Cl2P2Pd: C, 50.23; H, 8.08. Found C, 51.03; H, 8.26. MS 
(ESI): m/z 501.21 (M-2Cl).  
trans-[PdCl2(a5-PhobPiBu)2] (5b). Yield: 0.0393 g (0.068 mmol, 54%). 31P{1H} NMR (298 K, 
121 MHz, CD2Cl2): δP 46.5 (s), 45.9 (s).  31P{1H} NMR (373 K, 121 MHz, C2H2Cl4): δP 46.4 (s). 
13C{1H} NMR (500 MHz, CD2Cl2): δC 35.6 (t, JPC 12.4 Hz), 32.5 (s), 30.7 (t, JPC 2.86 Hz), 25.7 
(br s), 24.6 (t, JPC 3.81 Hz). 1H NMR (400 MHz, CD2Cl2): δH 2.73 (4H, s), 2.60-2.35 (6H, br m), 
2.27-2.13 (8H, br m), 1.71 (4H, q), 1.62-1.40 (12H, br m), 1.18 (6H, d), 1.16 (6H, d). Anal. Calcd 
for C26H46Cl2P2Pd: C, 50.23; H 8.08. Found 50.86; H, 8.29. MS (ESI): m/z 536.18 (M-Cl), 
501.20 (M-2Cl). 
trans-[PdCl2(a7-PhobPnBu)2] (6a).  Yield: 0.0248 g (0.051 mmol, 34%). 31P{1H} NMR (298 
K, 121 MHz, CD2Cl2): δP 39.5. 31P{1H} NMR (173 K, 121 MHz, CH2Cl2): δP 40.1 (s), 39.7 (s). 
13C{1H} NMR (500 MHz, CD2Cl2): δC 32.4 (t, JPC 12.4 Hz), 31.5 (t, JPC 1.91 Hz), 29.5 (t, JPC 
8.58 Hz), 29.0 (t, JPC 2.86 Hz), 25.2 (s), 24.1 (t, JPC 5.72 Hz), 20.0 (t, JPC 7.63 Hz), 13.6 (s). 1H 
NMR (500 MHz, CD2Cl2): δH 3.15 (4H, br s), 2.36 (4H, br s), 2.14 (2H, s), 1.91-1.51 (18H, br s), 
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0.98 (6H, t). Anal. Calcd for C26H46Cl2P2Pd: C, 50.23; H, 8.08. Found C, 50.22; H, 8.15. MS 
(ESI): m/z 501.21 (M-2Cl). 
trans-[PdCl2(a7-PhobPiBu)2] (6b). Yield: 0.0345 g (0.060 mmol, 48%). 31P{1H} NMR (298 K, 
121 MHz, CD2Cl2): δP 38.6 (s). 31P{1H} NMR (173 K, 121 MHz, CH2Cl2): δP 38.5 (s), 38.1 (s). 
13C{1H} NMR (500 MHz, CD2Cl2): δC 33.0 (t, JPC 12.4 Hz), 31.7 (s), 30.6 (s), 29.5 (s), 29.5 (t, 
JPC 2.86 Hz), 29.4 (s), 27.7 (t, JPC 1.91 Hz), 25.1 (s), 23.9 (t, JPC 4.77 Hz). 1H NMR (400 MHz, 
CD2Cl2): δH 3.12 (4H, br s), 2.49-2.37 (6H, br m), 2.13 (8H, s), 1.96-1.63 (22 H, br m), 1.15 (6H, 
t). Anal. Calcd for C26H46Cl2P2Pd: C, 50.23; H, 8.08. Found 50.42; H, 8.23. MS (ESI): m/z 
536.18 (M-Cl), 501.20 (M-2Cl). 
Crystal structure determinations. X-ray diffraction experiments on all crystals were carried 
out at 100 K on a Bruker APEX II diffractometer using Mo-Kα radiation (λ = 0.71073 Å). Data 
collections were performed using a CCD area detector from a single crystal mounted on a glass 
fibre. Intensities were integrated24 from several series of exposures measuring 0.5° in ω or φ. 
Absorption corrections were based on equivalent reflections using SADABS.25 The structures 
were solved using SHELXS and refined against all Fo2 data with hydrogen atoms riding in 
calculated positions using SHELXL.26 Crystal structure and refinement data are given in Table 3. 
Minor disorder of the phobane ring was modeled for 2a (36%), 3b (22%), 5b (50%) and 6b 
(25%), whilst 5b had dynamic disorder of one its iBu substituent (16%). Data for crystal 2b were 
twinned. The different components of the non-merohedral twins were assigned using the Bruker 
program CELL_NOW27 and corrected for absorption with TWINABS28. The difference map 
shows large features (ca. 4 eÅ-3) close to (≤ 1 Å) the platinum and palladium atoms, presumably 
due to absorption effects, but no features of chemical significance. Collection of data for crystal 
2a was not completed to normal levels of completeness due to instrument failure. 
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Computational Details. DFT calculations were computed in the gas-phase with the Jaguar 
program,29 using the standard hybridized functional B3LYP30 and basis-set combination 6-31G 
for all atoms, with the exception of Pd and Pt atoms for which the effective core potential 
LACV3P basis set was used instead. Rotations were carried out in increments of 30° by 
constraining the Cl-metal-P-C1R torsion. 
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Table 3 Crystal data. 
Compound s-PhobP(Se)nBu a7-PhobP(Se)nBu a5-PhobP(Se)nBu 
Color, habit colorless block  colorless block  colorless block  
Size/mm 0.67×0.16×0.14 0.24×0.18×0.18 0.35×0.26×0.22 
Empirical 
Formula 
C12H23PSe C12H23PSe C12H23PSe 
M 277.23 277.23 277.23 
Crystal system triclinic triclinic monoclinic 
Space group P-1 P-1 P21/n 
a/Å 7.0652(10) 7.3002(2) 11.9319(4) 
b/Å 9.8344(14) 9.1583(2) 8.9612(3) 
c/Å 10.6283(16) 10.1355(2) 13.2301(5) 
α/° 115.834(6) 111.174(1) 90.00 
β/° 101.468(5) 93.095(1) 113.1560(10) 
γ/° 92.320(6) 92.187(1) 90.00 
V/Å3 644.60(16) 629.75(3) 1300.65(8) 
Z 2 2 4 
µ/mm-1 3.001 3.072 2.975 
T/K 120 100 100 
θmin,max 3.65,36.21 2.57,27.63 1.95,27.53 
Completeness 0.975 to θ = 27.50° 0.990 to θ = 27.63° 0.998 to θ = 27.53° 
Reflections: 
total/independent 
18717/4408 18811/2897 15293/2992 
Rint 0.0291 0.0209 0.0221 
Final R1 and 
wR2 
0.0151, 0.0402 0.0228, 0.0610 0.0191, 0.0503 
Largest peak, 
hole/eÅ-3 
0.380, -0.299 0.596, -0.378 0.640, -0.270 





Compound 2a 4a 
Color, habit colorless block yellow block 




M 662.54 573.85 
Crystal system monoclinic triclinic 
Space group P21/n P-1 
a/Å 8.1637(6) 7.7650(3) 
b/Å 7.8841(6) 7.8175(4) 
c/Å 20.4032(17) 11.0564(5) 
α/° 90.00 97.289(3) 
β/° 98.787(6) 103.064(3) 
γ/° 90.00 96.625(3) 
V/Å3 1311.67(18) 641.25(5) 
Z 2 1 
µ/mm-1 5.684 1.067 
T/K 100 100 
θmin,max 2.74,28.48 1.91,27.48 




Rint 0.0652 0.0252 









Compound 1b 2b 3b 
Color, habit colorless plate yellow prism yellow block 
Size/mm 0.55×0.46×0.32 0.20×0.28×0.37 0.25×0.134×0.11 
Empirical 
Formula 
C24H46Cl2P2Pt C24H46Cl2P2Pt C24H46Cl2P2Pt 
M 662.54 662.54 662.54 
Crystal system triclinic monoclinic monoclinic 
Space group P-1 P21/n P21/c 
a/Å 8.3578(3) 11.9830(10) 10.0716(13) 
b/Å 9.1768(3) 12.2971(10) 17.273(2) 
c/Å 9.3694(3) 18.1806(16) 15.466()2) 
α/° 85.464(2) 90.00 90.00 
β/° 65.173(2) 101.331(5) 93.564(7) 
γ/° 86.866(2) 90.00 90.00 
V/Å3 649.97(4) 2626.8(4) 2685.3(6) 
Z 1 4 4 
µ/mm-1 5.736 5.677 5.553 
T/K 100 100 100 
θmin,max 2.23,27.50 2.40,21.42 1.77,27.56 
Completeness 0.998 to θ = 27.50° 0.971 to θ = 32.35° 0.995 to θ = 27.56° 
Reflections: 
total/independent 
10950/2984 9243/9243 89368/6172 
Rint 0.0207 - 0.0295 
Final R1 and wR2 0.0180,0.0456 0.0645,0.1073 0.0189,0.0441 
Largest peak, 
hole/eÅ-3 
1.644,-0.967 4.432,-2.283 2.080,-1.384 





Compound 4b 5b 6b 
Color, habit yellow plate yellow plate colorless plate 
Size/mm 0.46×0.34×0.21 0.55×0.41×0.34 ×× 
Empirical 
Formula 
C24H46Cl2P2Pd C24H46Cl2P2Pd C24H46Cl2P2Pd 
M 573.85 573.85 573.85 
Crystal system triclinic monoclinic monoclinic 
Space group P-1 C2/c P21/c 
a/Å 8.3609(7) 19.5252(5) 10.0704(3) 
b/Å 9.1728(9) 16.2838(4) 17.3101(4) 
c/Å 9.3913(9) 8.8634(2) 15.4017(4) 
α/° 85.750(5) 90.00 90.00 
β/° 64.862(5) 109.9410(10) 93.5110(10) 
γ/° 86.813(5) 90.00 90.00 
V/Å3 650.00(10) 2649.11(11) 2679.78(12) 
Z 1 4 4 
µ/mm-1 1.052 1.033 1.021 
T/K 100 100 100 
θmin,max 2.40,25.74 2.22,26.47 2.65,42.32 
Completeness 0.982 to θ = 25.74° 0.998 to θ = 
27.52° 




14405/2442 28470/3062 72832/18812 
Rint 0.0902 0.0388 0.0299 
Final R1 and wR2 0.0692,0.1808 0.0296,0.720 0.0433,0.0933 
Largest peak, 
hole/eÅ-3 
3.178,-1.386 0.672,-0.352 3.499,-2.663 
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